Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INTX 231
- Development stage
- Preclinical
- Lead developer
- InteguRx Therapeutics
- Modality
- Small Molecules
- Administration
- Topical, Transdermal
01
Overview
**INTX 231** is an investigational transdermal gel developed by InteguRx Therapeutics for the treatment of nausea and vomiting in pregnancy. Publicly available information identifies it as a patented transdermal therapeutic product, but the exact active ingredient composition and molecular target have not been clearly disclosed in reliable primary public sources. Based on the disclosed program profile, it appears to be a pharmaceutical drug-delivery product intended to provide non-oral treatment for pregnancy-related nausea and vomiting, potentially offering an alternative to standard oral therapies in this setting.
Beyond the preview
Go deeper on INTX 231.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INTX 231.